MILAN--(BUSINESS WIRE)--On the heels of AAVantgarde closing a Series B financing round, AGC Biologics announced a new manufacturing agreement with the biotechnology company, marking AGC Biologics’ ...
Gene therapies can correct diseases at their genetic core, but their success hinges on viral vector manufacturing. As gene therapy technology becomes more advanced, producing viral vectors becomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback